These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 25803343)
1. Naltrexone extended-release plus bupropion extended-release for treatment of obesity. Yanovski SZ; Yanovski JA JAMA; 2015 Mar 24-31; 313(12):1213-4. PubMed ID: 25803343 [No Abstract] [Full Text] [Related]
2. Contrave--a combination of bupropion and naltrexone for weight loss. Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849 [No Abstract] [Full Text] [Related]
3. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. Ali KF; Shukla AP; Aronne LJ Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740 [TBL] [Abstract][Full Text] [Related]
4. [Mysimba, an American appetite suppressant and the logic of the single European market]. Nau JY Rev Med Suisse; 2015 Apr; 11(470):890-1. PubMed ID: 26050313 [No Abstract] [Full Text] [Related]
6. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Verpeut JL; Bello NT Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397 [TBL] [Abstract][Full Text] [Related]
7. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Halpern B; Mancini MC Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121 [TBL] [Abstract][Full Text] [Related]
9. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Apovian CM Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384 [TBL] [Abstract][Full Text] [Related]
10. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Hong K; Herrmann K; Dybala C; Halseth AE; Lam H; Foreyt JP Clin Obes; 2016 Oct; 6(5):305-12. PubMed ID: 27477337 [TBL] [Abstract][Full Text] [Related]
11. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E; Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728 [TBL] [Abstract][Full Text] [Related]
12. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Makowski CT; Gwinn KM; Hurren KM Obes Facts; 2011; 4(6):489-94. PubMed ID: 22249001 [TBL] [Abstract][Full Text] [Related]
13. Obesity Epidemic: Pharmaceutical Weight Loss. Curry SA R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654 [TBL] [Abstract][Full Text] [Related]
14. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Bello NT Expert Opin Drug Saf; 2019 Jul; 18(7):549-552. PubMed ID: 31092063 [No Abstract] [Full Text] [Related]
15. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? Citrome L Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190 [No Abstract] [Full Text] [Related]
16. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. Pi-Sunyer X; Apovian CM; McElroy SL; Dunayevich E; Acevedo LM; Greenway FL Int J Obes (Lond); 2019 Oct; 43(10):2085-2094. PubMed ID: 30664661 [TBL] [Abstract][Full Text] [Related]
17. Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Buehler AM Drug Des Devel Ther; 2015; 9():419-23. PubMed ID: 25609921 [No Abstract] [Full Text] [Related]
18. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA; J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734 [TBL] [Abstract][Full Text] [Related]